UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 8, 1994
AMERICAN CYANAMID COMPANY
(Exact name of registrant as specified in charter)
Commission file number 1-3426
MAINE 13-0430890
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization Identification No.)
ONE CYANAMID PLAZA, WAYNE, NJ 07470
(Address of principal executive offices)
(201) 831-2000
(Registrant's telephone number, including area code)
<PAGE>
Item 5. Other Events.
On July 8, 1994, American Cyanamid Company ("Cyanamid")
announced that it has agreed in principle to sell its Davis & Geck
wound management business to its European joint venture partner, B.
Braun Melsungen AG of Germany, for proceeds of approximately
$220,000,000, which include an intermediate term dividend-paying
preferred stock investment in the combined B. Braun and Davis &
Geck business. Cyanamid also will enter into a multi-year
manufacturing agreement with B. Braun and will continue to own and
operate its major suture plant in Manati, Puerto Rico. The sale is
subject to the finalization of definitive agreements and required
government approvals.
B. Braun is a privately held, research-based company, that
develops and manufactures specialty medical products for surgical
and hospital use and markets them throughout the world. Cyanamid
and B. Braun currently are partners in joint venture wound
management companies in Germany, Portugal and Spain. Davis & Geck
has operations in 60 countries, and had 1993 sales of approximately
$300,000,000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
AMERICAN CYANAMID COMPANY
(Registrant)
By:R. T. Ritter____________
R. T. Ritter
Controller and Principal
Accounting Officer
July 19, 1994
